Susan Abushakra is the founder of Alzheon. Alzheon has raised $60M in total funding. Latest round: Series D. Based in Framingham, Massachusetts.
Susan Abushakra, M.D., is the Chief Medical Officer at Alzheon, a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Prior to joining Alzheon, Dr. Abushakra was the Chief Medical Officer at Transition Therapeutics and Elan/Perrigo. She has 15 years of neurological drug development expertise, including leadership roles at Elan Corporation, Allergan, Eisai, and Wyeth, working on drug candidates for neurological and psychiatric disorders, with a particular focus on Alzheimer's disease.
Full founder directory · Investor directory · Company funding database · Fundraising library